{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:14:28Z","timestamp":1789121668792,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,5,15]],"date-time":"2018-05-15T00:00:00Z","timestamp":1526342400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s10557-018-6795-9","type":"journal-article","created":{"date-parts":[[2018,5,15]],"date-time":"2018-05-15T04:08:14Z","timestamp":1526357294000},"page":"287-294","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Ticagrelor Versus Clopidogrel as Part of Dual or Triple Antithrombotic Therapy: a Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2912-1928","authenticated-orcid":false,"given":"Ioannis","family":"Andreou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Briasoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Pappas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignatios","family":"Ikonomidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Alexopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,15]]},"reference":[{"key":"6795_CR1","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s10557-017-6730-5","volume":"31","author":"D Alexopoulos","year":"2017","unstructured":"Alexopoulos D, Vlachakis P, Lekakis J. Triple antithrombotic therapy in atrial fibrillation patients undergoing PCI: a fading role. Cardiovasc Drugs Ther. 2017;31:319\u201324.","journal-title":"Cardiovasc Drugs Ther"},{"key":"6795_CR2","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ijcard.2015.12.005","volume":"205","author":"J Liu","year":"2016","unstructured":"Liu J, Fan M, Zhao J, Zhao B, Zhang C, Liu C, et al. Efficacy and safety of antithrombotic regimens after coronary intervention in patients on oral anticoagulation: traditional and Bayesian meta-analysis of clinical trials. Int J Cardiol. 2016;205:89\u201396.","journal-title":"Int J Cardiol"},{"key":"6795_CR3","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","volume":"381","author":"WJ Dewilde","year":"2013","unstructured":"Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381:1107\u201315.","journal-title":"Lancet"},{"key":"6795_CR4","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.ijcard.2016.11.160","volume":"228","author":"YG Xin","year":"2017","unstructured":"Xin YG, Zhang HS, Li YZ, Guan QG, Guo L, Gao Y, et al. Efficacy and safety of ticagrelor versus clopidogrel with different dosage in high-risk patients with acute coronary syndrome. Int J Cardiol. 2017;228:275\u20139.","journal-title":"Int J Cardiol"},{"key":"6795_CR5","unstructured":"Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2017:2017."},{"key":"6795_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.","journal-title":"BMJ"},{"key":"6795_CR7","doi-asserted-by":"crossref","unstructured":"Higgins JP. Cochrane handbook for systematic reviews of interventions. John Wiley & Sons Ltd, West Sussex. 2008.","DOI":"10.1002\/9780470712184"},{"key":"6795_CR8","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360.","journal-title":"BMJ"},{"key":"6795_CR9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0140-6736(97)08461-4","volume":"351","author":"J Pogue","year":"1998","unstructured":"Pogue J, Yusuf S. Overcoming the limitations of current meta-analysis of randomised controlled trials. Lancet. 1998;351:47\u201352.","journal-title":"Lancet"},{"key":"6795_CR10","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/S0197-2456(97)00051-2","volume":"18","author":"JM Pogue","year":"1997","unstructured":"Pogue JM, Yusuf S. Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis. Control Clin Trials. 1997;18:580\u201393. discussion 661-586","journal-title":"Control Clin Trials"},{"key":"6795_CR11","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","volume":"375","author":"CM Gibson","year":"2016","unstructured":"Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375:2423\u201334.","journal-title":"N Engl J Med"},{"key":"6795_CR12","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","volume":"377","author":"CP Cannon","year":"2017","unstructured":"Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377:1513\u201324.","journal-title":"N Engl J Med"},{"key":"6795_CR13","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1016\/S0140-6736(17)30751-1","volume":"389","author":"EM Ohman","year":"2017","unstructured":"Ohman EM, Roe MT, Steg PG, James SK, Povsic TJ, White J, et al. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet. 2017;389:1799\u2013808.","journal-title":"Lancet"},{"key":"6795_CR14","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1016\/j.amjcard.2008.08.021","volume":"102","author":"R Rossini","year":"2008","unstructured":"Rossini R, Musumeci G, Lettieri C, Molfese M, Mihalcsik L, Mantovani P, et al. Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy. Am J Cardiol. 2008;102:1618\u201323.","journal-title":"Am J Cardiol"},{"key":"6795_CR15","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.jacc.2006.11.044","volume":"49","author":"DJ Angiolillo","year":"2007","unstructured":"Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, et al. Variability in individual responsiveness to clopidogrel. clinical implications, management, and future perspectives J Am Coll Cardiol. 2007;49:1505\u201316.","journal-title":"clinical implications, management, and future perspectives J Am Coll Cardiol"},{"key":"6795_CR16","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S0140-6736(13)61170-8","volume":"382","author":"GW Stone","year":"2013","unstructured":"Stone GW, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC, et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet. 2013;382:614\u201323.","journal-title":"Lancet"},{"key":"6795_CR17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/clc.22486","volume":"39","author":"A Fu","year":"2016","unstructured":"Fu A, Singh K, Abunassar J, Malhotra N, Le May M, Labinaz M, et al. Ticagrelor in triple antithrombotic therapy: predictors of ischemic and bleeding complications. Clin Cardiol. 2016;39:19\u201323.","journal-title":"Clin Cardiol"},{"key":"6795_CR18","doi-asserted-by":"crossref","unstructured":"Jackson LR, 2nd, Ju C, Zettler M, Messenger JC, Cohen DJ, Stone GW, et al. Outcomes of patients with acute myocardial infarction undergoing percutaneous coronary intervention receiving an oral anticoagulant and dual antiplatelet therapy: A comparison of clopidogrel versus prasugrel from the TRANSLATE-ACS study JACC Cardiovasc Interv 2015;8:1880\u20131889.","DOI":"10.1016\/j.jcin.2015.08.018"},{"key":"6795_CR19","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1016\/j.jacc.2013.02.036","volume":"61","author":"N Sarafoff","year":"2013","unstructured":"Sarafoff N, Martischnig A, Wealer J, Mayer K, Mehilli J, Sibbing D, et al. Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. J Am Coll Cardiol. 2013;61:2060\u20136.","journal-title":"J Am Coll Cardiol"},{"key":"6795_CR20","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ijcard.2017.05.119","volume":"243","author":"KW Chang","year":"2017","unstructured":"Chang KW, Arbit B, Hsu JC. Antithrombotic regimens in patients with atrial fibrillation and coronary artery disease after percutaneous coronary intervention: a focused review. Int J Cardiol. 2017;243:263\u20139.","journal-title":"Int J Cardiol"},{"key":"6795_CR21","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","volume":"68","author":"GN Levine","year":"2016","unstructured":"Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol 2016;68. 2016;68:1082\u2013115.","journal-title":"J Am Coll Cardiol 2016;68"},{"key":"6795_CR22","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.cjca.2016.07.591","volume":"32","author":"L Macle","year":"2016","unstructured":"Macle L, Cairns J, Leblanc K, Tsang T, Skanes A, Cox JL, et al. 2016 focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation. Can J Cardiol. 2016;32:1170\u201385.","journal-title":"Can J Cardiol"},{"key":"6795_CR23","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.thromres.2014.10.016","volume":"135","author":"OO Braun","year":"2015","unstructured":"Braun OO, Bico B, Chaudhry U, Wagner H, Koul S, Tyden P, et al. Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome. Thromb Res. 2015;135:26\u201330.","journal-title":"Thromb Res"},{"key":"6795_CR24","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ahj.2016.07.015","volume":"180","author":"S Sra","year":"2016","unstructured":"Sra S, Tan MK, Mehta SR, Fisher HN, Dery JP, Welsh RC, et al. Ischemic and bleeding events in patients with myocardial infarction undergoing percutaneous coronary intervention who require oral anticoagulation: insights from the Canadian observational AntiPlatelet sTudy. Am Heart J. 2016;180:82\u20139.","journal-title":"Am Heart J"},{"key":"6795_CR25","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1177\/1074248417698042","volume":"22","author":"NJ Verlinden","year":"2017","unstructured":"Verlinden NJ, Coons JC, Iasella CJ, Kane-Gill SL. Triple antithrombotic therapy with aspirin, P2Y12 inhibitor, and warfarin after percutaneous coronary intervention: an evaluation of prasugrel or ticagrelor versus clopidogrel. J Cardiovasc Pharmacol Ther. 2017;22:546\u201351.","journal-title":"J Cardiovasc Pharmacol Ther"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10557-018-6795-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-018-6795-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-018-6795-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T18:08:06Z","timestamp":1661278086000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-018-6795-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,15]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["6795"],"URL":"https:\/\/doi.org\/10.1007\/s10557-018-6795-9","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,15]]},"assertion":[{"value":"15 May 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Alexopoulos reports advisory board fees (modest) from AstraZeneca, Boehringer Ingelheim, Bayer, and Medtronic and speaker honoraria (modest) from AstraZeneca, Bayer, and Boehringer Ingelheim. Other authors have no conflicting interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}